Gradient Investments’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

Gradient Investments’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$637	–	1898
2023 Q4	$637	Buy	+100	New	+$536	﹤0.01%	1538

Gradient Investments's FRLN Position: Q1 2024 in Review

Gradient Investments sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 100 shares — an estimated $637 sold.

Gradient Investments first reported a position in FRLN in Q4 2023 and held it in 1 quarter. The position peaked at $637 in Q4 2023. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

Gradient Investments reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Gradient Investments sold 100 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $637.
Gradient Investments first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q4 2023 and held it in 1 quarter.
Gradient Investments's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $637 in Q4 2023.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.